CLINICAL STUDY AGREEMENT PROTOCOL: B-701-U21 SITE: 420-001XXXXX BIOCLINTHERAPEUTICS, INC. 12 FEBRUARY2018 VERSION: VERSION#1 COUNTRY: CZECH REPUBLIC SMLOUVA O KLINICKÉ STUDII PROTOKOL: B-701-U21 PRACOVIŠTĚ: 420-001 XXXXX BIOCLINTHERAPEUTICS,INC....Clinical Study Agreement • February 16th, 2018
Contract Type FiledFebruary 16th, 2018CLINICAL STUDY AGREEMENTThis clinical study agreement (“Agreement”), effective as of the day of publication in the Contracts Registry (the “Effective Date”), is entered into by and among BioClin Therapeutics, Inc., with its TAX ID number 27-3630029 and principal office and place of business at 130 Market Place, PMB #295, San Ramon, California 94583, USA ("Sponsor”) ; andVseobecna fakultni nemocnice v Praze, with its principal office at U Nemocnice 499/2, 128 08 Praha 2, Czech Republic, ID: 000 641 65, represented by XXXXX ("Institution”).Sponsor and Institution are referred to individually herein as a “Party” and collectively as parties (the “Parties”). WHEREAS, Sponsor is sponsoring a clinical study of its proprietary product referred to as B- 701 (the “Study Drug”), in accordance with Protocol No. B-701-U21, titled “A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Lo